Prenetics Global (Prenetics Global) Debt-to-Asset : 0.02 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Debt-to-Asset?

Prenetics Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.2 Mil. Prenetics Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $3.1 Mil. Prenetics Global's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $276.4 Mil. Prenetics Global's debt to asset for the quarter that ended in Sep. 2023 was 0.02.

Prenetics Global Debt-to-Asset Historical Data

The historical data trend for Prenetics Global's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Debt-to-Asset Chart

Prenetics Global Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

0.02

0.04

0.02

Prenetics Global Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial								0.05	0.02	0.02	0.02	0.02

Competitive Comparison of Prenetics Global's Debt-to-Asset

For the Diagnostics & Research subindustry, Prenetics Global's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prenetics Global's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Prenetics Global's Debt-to-Asset falls into.

Prenetics Global Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Prenetics Global's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.883	+	3.763)	/	312.131
	=	0.02

Prenetics Global's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.195	+	3.063)	/	276.415
	=	0.02

Prenetics Global (NAS:PRE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Prenetics Global Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.